Actelion issues invitation to 2015 Annual General Meeting of Shareholders

Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2015 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

ALLSCHWIL/BASEL, SWITZERLAND - 10 April 2015 - Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting will take place on Friday, 8 May 2015 (10:00hrs CEST) at the Congress Center, Messe Basel, Switzerland.

At this year's meeting the Board of Directors is proposing an increase in the dividend payment to CHF 1.30 per share. Also, following the approval of the Articles of Association at the 2014 AGM, the Board is proposing for the first time the approval of a maximum compensation for the non-executive members of the Board of Directors and the maximum compensation amount for the Actelion Executive Committee.

After 10 and 15 years of service on Actelion's Board of Directors, respectively, Mr. Carl Feldbaum and Mr. Werner Henrich will be stepping down at the AGM. All other Board members will stand for re-election.

Jean-Pierre Garnier, Chairman of the Board of Directors, commented: "Personally, I enjoyed working with both Carl and Werner, who have greatly supported Actelion during their long service as integral members on Actelion's Board of Directors. Their individual contributions to the success of Actelion will be duly celebrated at the AGM."

In addition to the regular agenda items, the Board is proposing the election of two new Directors: Mrs. Herna Verhagen, Chief Executive Officer of PostNL N.V., and Mr. David Stout, a pharmaceutical industry professional who has announced his resignation from the Board of Shire, plc. at the end of April 2015.

Jean-Pierre Garnier, concluded: "As a current CEO of a company with a very complex business model, Herna understands the challenges of operating in the current economic and business climate. David brings a broad experience of the pharmaceutical business having spent his entire professional career in global pharma. I am confident that both professionals will make a significant contribution to Actelion, should our shareholders decide to elect them to the Board."